1.GLOBOCAN 2012: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. All Cancers (excluding non-melanoma skin cancer) (base de datos en internet). Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Acceso: abril 2014.
2.GLOBOCAN 2012: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Breast Cancer (base de datos en internet). Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Acceso: abril 2014.
3.Registro Nacional del Cáncer. Sección Independiente para el Control del Cáncer (SICC). Cuba. Incidencia de cáncer por todas las localizaciones según sexo y provincia. 2010.
4.Anuario Estadístico de Salud 2012. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Ministerio de Salud Pública. Cuba. Principales causas de muerte de 80 años y más de edad. 2000, 2011 - 2012
5.Anuario Estadístico de Salud 2012. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Ministerio de Salud Pública. Cuba. Mortalidad por algunos tumores malignos. 2000, 2011 - 2012
6.Reis-Filho JS1, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-23.
7. Comen EA, Fornier MN. Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. Clin Breast Cancer. 2010;10 Suppl 2:S7-19. doi: 10.3816/CBC.2010.s.008.
8.Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, et al. Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. Ann Oncol. 2014;25(4):773-80.
9.Alizart M, Saunus J, Cummings M, Lakhani SR. Molecular classification of breast carcinoma. Diagnostic Histopathology. 2012;18(3):97-103
10.Khadakban D, Gorasia-Khadakban T, Vijaykumar DK, Pavithran K, Anupama R. Factors associated with better survival after surgery in metastatic breast cancer patients. Indian J Surg Oncol. 2013;4(1):52-8.
11.Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698-707.
12.Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012;134(1):13-20.
13.Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, et al. Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs. 2006;17(5):565-70.
14.Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, et al. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol. 2003;21(9):1819-24.
15.Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128(1):155-63.
16.Thriveni K, Deshmane V, Ramaswamy G, Krishnamoorthy L. Diagnostic Significance of CA15-3 with Combination of HER-2/neu Values at 85th Percentiles in Breast Cancer. Indian J Clin Biochem. 2013;28(2):136-40.
17.Jung SY, Rosenzweig M. Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message? Front Public Health. 2013;1:49.
18.Fulton A, Miller F, Weise A, Wei WZ. Prospects of controlling breast cancer metastasis by immune intervention. Breast Dis. 2006-2007;26:115-27.
19.Lang JE, Babiera GV. Locoregional Resection in Stage IV Breast Cancer: Tumor Biology, Molecular and Clinical Perspectives. Surg Clin N Am. 2007;87:527–538.
20.Rapiti E, Verkooijen HM, Vlastos G. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–2749.
21.Ruiterkamp J, Ernst MF, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol. 2009;35:1146–1151.
22.Cristofanilli M, Budd GT, Ellis MJ. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
23.Senkus E, Cardoso F, Pagani O. Time for more optimism in metastatic breast cancer? Cancer Treat Rev. 2014;40(2):220-8.
24.Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19.
25.Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, et al. A phase II study of docetaxel and vinorelbine plus filgrastim for HER2 negative, stage IV breast cáncer: SWOG S0102. Breast Cancer Res Treat. 2014;143:351-358
26.Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435-44.
27.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines. Breast Cancer. Versión 1.2014. Disponible en: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Acceso: abril 2014
28.Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013;19(1):28-33.
29.Von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299-309.
30.Miyake M, Hashimoto K, Ito M, Ogawa O, Arai E, Hitomi S, et al.The abnormal occurrence and the differentiation-dependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumors. Cancer. 1990;65(3):499-505.
31.Durrant LG, Noble P, Spendlove I. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol. 2012;167(2):206-15.
32.Wiegandt H. The chemical structures of gangliosides. En: Oettgen HF, Ed. Gangliosides and cancer, VCH Publishers, New York, 1989.
33.Herberman RB. Tumor immunology. JAMA. 1992;268:2935-2939.
34.Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 78:45, 1987.
35.Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 2010;12(3):204.
36.Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res. 1996;56(22):5165-71.
37.Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 1999; 18(1-2):190-7.
38.Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3(1):71-81.
39.Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2006; 6:691-710.
40.Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-75.
41.Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, et al. A Mouse IgG1 Monoclonal Antibody Specific for N-GlycolylGM3 Ganglioside Recognized Breast and Melanoma Tumors. HYBRIDOMA. 2000; 19(3):241-247.
42.Blanco R, Quintana Y, Blanco D, Cedeño M, Rengifo CE, Frómeta M, et al. Tissue reactivity of the 14F7 Mab raised against NGlycolylGM3 ganglioside in tumors of neuroectodermal, mesodermal and epithelial origin. Journal of Biomarkers. 2013
43.Blanco R, Blanco D, Quintana Y, Escobar X, Rengifo CE, Osorio M, et al. Immunoreactivity of the 14F7 Mab raised against NGlycolylGM3 ganglioside in primary lymphoid tumors and lymph node metastasis. Patholog Res Int. 2013; 2013:920972. Epub 2013 Nov 28),
44.Bada A, Casaco A, Arteaga M, Martinez J, Leon A, Santana E, et al. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month Study. Hum Exp Toxicol. 2002;21(5):263-7.
45.Labrada M, Clavell M, Bebelagua Y, León J, Alonso DF, Gabri MR, et al. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther. 2010;10(2):153-62.
46.Labrada M. Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine. Human Vaccines and Immunotherapeutics. En prensa 2014.
47.Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K. Enhancement of the antitumor activity of ionising radiation by Nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008;98:749-55.
48. Garrido G, Sánchez B, Pérez R, Fernández LE (2007) The anti-tumor activity of the 7A7 antibody, specific to murine EGFR, is independent of target expression levels in immunocompetent mice. Biotecnología Aplicada 24:26-32.
49. Garrido G, Lorenzano P, Sánchez B, Beausoleil I, Alonso DF, Pérez R, Fernández LE (2007) T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother 56:1701-1710.)
50. Carr A, Rodríguez E, Arango MC, Camacho R, Osorio M, Gabri M, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol. 2003;21(6):1015-21.
51. Registro Clínico. Inmunoterapia activa específica con la vacuna NGcGM3/VSSP/Montanide ISA 51 en pacientes con cáncer de mama metastásico. Fase II. Disponible en: http://registroclinico.sld.cu/en/trials/RPCEC00000068-En
52. De la Torre A, Hernández J, Ortiz R, Cepeda M, Pérez K, Car A, et al. NGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: results of Phase I/IIa clinical trial. Breast Cancer (Auckl). 2012;6:151-7.
53.Osorio M, Gracia E, Reigosa E, Hernández J, de la Torre A, Saurez G, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manaq Res. 2012;4:341-5.
54. Pérez R., Betsholtz C., Westermark B. Frequent expression of growth factors for messenquimal cells in human mamary carcinoma cell lines. Cancer Research 1987; 47, 3425-3429.
55. Dobashi Y., Stren DF., Membrane anchored form of EGF stimulate focus formation and intercellular comunication. Oncogene. 1991; 6:1151-1159.
56. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54.
57. Verduzco-Rodriguez L, Aguirre-Gonzalez EH, Verduzco-Aguirre HC. Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. Hematol Oncol Stem Cell Ther 2011;4:182-4.
58. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR. Cancer Biol Ther 2010;10.
59. Crombet T. Use the humanized anti-EGFR MAb (nimotuzumab) and radiotherapy for the treatment of high grade glioma patients European Journal of Cancer, suppl 2008 6:168.
60. Crombet T, Cabanas R, Alert J, et al. Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: preliminary results from a phase II study Eur J Cancer Suppl 2009;7
61. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012;13:600-5.
62. Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2010.
63. Macias A, Neninger E, Santiesteban E, et al. Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases. Eur J Cancer 2008;Suppl:160-1.
64.Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54.
65. Clinical Study Report Protocol Number YMB1000/004 “An Open Phase I Dose Escalation Study to Assess the Safety of TheraCIM-hR3 (Ymb1000), (h-R3) in Conjunction with Radiotherapy in Patients with Advanced (Unresectable) Squamous Cell Carcinoma of the Head and Neck Who are Suitable for Radiotherapy”. June 27, 2007.
66. Rodriguez MO, Rivero TC, Bahi RD, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of de head and neck. Cancer Biology & Therapy, 2010; 9(5):343-349.
67. Ramakrishnan MS, Eswaraiah A, Crombet- Ramos T, Piedra p y col. Nimotuzumab, a promising therapeutic monoclonal antibody for treatment of tumors of epitelial origin. mAbs 1:1, 41-48;january/feruary 2009.
68. Solomon MT, Selva JC, Figueredo J, et al. Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients. J Clin Oncol 2012;30.
69. Soriano JL, Ramos Suzarte M, Wilkison B, Viada CE, Garcia, E, Jiménez G, et al. Tratamiento del cáncer de mama avanzado con el anticuerpo monoclonal hR3 en combinación con doxorrubicina y ciclofosfamida. EC Fase I. Ciudad de la Habana, 2003.
70. Crombet T, Torres O, Neninger E, Catala M, Rodriguez N, Ramos M, Fernandez E, Iznaga N, Perez R, Lage A. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 2001;16:93-102.
71. Jia J, Cui Y, Lu M, Wang X, Li J, Li J, et al. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. Clin Transl Oncol. 2015. [Epub ahead of print]
72. Kataria T, Gupta D, Bisht SS, Goyal S, Basu T, Srivastava A, et al. Chemoradiation in elderly patients with head and neck cancers: a single institution experience. Am J Otolaryngol. 2015;36(2):117-21.
73. Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2): 305-12.
74. Müller K, Schlamann A, Guckenberger M, Warmuth-Metz M, Glück A, Pietschmann S, et al. Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.Strahlenther Onkol. 2014 Apr;190(4):377-81.
75. Qi D, Cui Y, Wang Q, Huang C, Xu J, Yang Y, et al. A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer. J Cancer Res Ther. 2015;11 Suppl:c32-7.
76. Yang QY, Guo CC, Chen ZP. Profile of nimotuzumab in the treatment of high-grade glioma. Onco Targets Ther. 2015;8:819-25.
77. Irie A, Koyamat S, Kozutsumi Y, Kawasaki T, Suzuki A. “The molecular basis for the absence of N-glycolylneuraminic acid in humans”. Journal of Biological Chemistry, vol. 273, no. 25, pp. 15866–15871, 1998.
78. Leeden RW, Yu RK. Chemistry and analysis of sialic acid. In: A.Rosemberg and C-L. Schengtrund (eds.) Biological Role of Sialic Acid, , pp 1- 48. New York: Plenum Press, 1976.
79. Wolff AC, Domchek SM, Davidson NE, Sacchini V, McCormick B. Cancer of the Breast. En: Abeloff´s Clinical Oncology. Elsevier Churchill Livingstone;2014. p. 1630-1692e9.
80. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
81. Peter F Thall and Eliu H Estey. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Statistics in Medicine. 1993; 12: 1197-1211.
